# A Study of AL8326 in Non-Small Cell Lung Cancer

> **NCT06794957** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **Advenchen Laboratories, LLC** · enrollment: 158 (estimated)

## Conditions studied

- Non-small Cell Lung Cancer

## Interventions

- **DRUG:** AL8326 tablets

## Key facts

- **NCT ID:** NCT06794957
- **Lead sponsor:** Advenchen Laboratories, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-05-19
- **Primary completion:** 2027-12
- **Final completion:** 2027-12
- **Target enrollment:** 158 (ESTIMATED)
- **Last updated:** 2025-01-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06794957

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06794957, "A Study of AL8326 in Non-Small Cell Lung Cancer". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT06794957. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*